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What is it? Fas is a cell-surface
receptor, and one of the main
triggers of death in cells of the
immune system. A cell bearing Fas
can be set on a cell death (apoptosis)
pathway when the ligand FasL
binds to Fas.
Also known as¼ Apo-1 (in Germany);
CD95 (by a few immunologists).
It came to prominence¼ in 1995 and
1996, when a signaling pathway
downstream of Fas was described,
providing the first molecularly
defined link between a cell-surface
receptor and the core cell death
machinery (see Figure).
Not to be confused with¼ Ras, a small
GTPase, or Fos, a transcription factor.
Where is it found? Fas is expressed at
various levels in a wide range of cell
types. But a cell carrying Fas isn’t
necessarily condemned to death;
fortunately, FasL expression is very
restricted and even once the
signalling pathway has been
triggered, it can be blocked
downstream of Fas.
Its known functions are¼ in the
elimination of activated
lymphocytes at the end of an
immune response; as part of the
mechanism by which
immunoprivileged sites such as the
eye and the testis evade the
immune system.
Why all the fuss about Fas? Fas
seems to be essential for killing off
the immune response before it goes
out of control. Mice bearing
spontaneous loss-of-function
mutations in Fas and FasL have
enlarged spleens and lymph glands,
and some mouse strains have a form
of autoimmunity, due to a defect in
the elimination of activated
lymphocytes. Mutations in Fas have
also been described in children with
autoimmune lymphoproliferative
syndrome (ALPS). Fas is now also
thought to be involved in cell death
outside the immune system,
especially in cancer and other non-
infectious diseases.
Who are its known associates? The
intracellular ‘death domain’ of Fas
binds to the FADD adaptor protein,
which in turn recruits caspase-8 (see
Figure), thereby initiating the
proteolytic cascade of events
characteristic of apoptosis. Fas also
interacts with Daxx, which sensitizes
cells to death, and with FAP-1, a
protein tyrosine phosphatase that
was reported some time ago to
inhibit cell death signaling but
which is now rather out of fashion.
Does Fas have any relatives? Fas is
related to tumour necrosis factor
receptor 1 (TNFR1), by virtue of its
extracellular cysteine-rich repeats,
and is therefore classified as a
member of the TNFR family, which
includes other death receptors, such
as DR3, DR4 and DR5, as well as
some cell-surface immunoreceptors.
Does it have commercial potential?
Yes. Increased Fas activity is
thought to be involved in fulminant
hepatitis (a severe form of the
disease) and in thyroiditis, in the
excess T-cell death that occurs in
AIDS, and in some cases of tissue
rejection following transplantation.
Decreased Fas signalling has been
associated with the lack of death of
certain types of tumour cell;
acquired FasL expression is another
way for tumour cells to evade the
immune system. So, there is interest
in interfering with Fas-induced cell
death, although this would have to
be done selectively; injection of
anti-Fas antibodies kills mice within
a few hours.
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The Fas signalling pathway. Assembly of the
Fas oligomer by FasL — expressed on
another cell or produced by the same cell
(as in the elimination of activated
lymphocytes) — triggers the cell death
(apoptosis) pathway. Cysteine-rich repeat,
green; death domain, orange; death effector
domain, blue, caspase domain, red.
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